Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.

Laporte, Régent; Kohan, Arash; Heitzmann, Joshua; Wisniewska, Halina; Toy, Jeannine; La, Erin; Tariga, Hiroe; Alagarsamy, Sudarkodi; Ly, Brian; Dykert, John; Qi, Steve; Wisniewski, Kazimierz; Galyean, Robert; Croston, Glenn; Schteingart, Claudio D; Rivière, Pierre J-M

Laporte, Régent; Kohan, Arash; Heitzmann, Joshua; Wisniewska, Halina; Toy, Jeannine; La, Erin; Tariga, Hiroe; Alagarsamy, Sudarkodi; Ly, Brian; Dykert, John; Qi, Steve; Wisniewski, Kazimierz; Galyean, Robert; Croston, Glenn; Schteingart, Claudio D; Rivière, Pierre J-M.

Affiliation

Laporte R; Ferring Research Institute, Inc., 4245 Sorrento Valley Boulevard, San Diego, CA 92121, USA. regent.laporte@ferring.com

J Pharmacol Exp Ther ; 337(3): 786-96, 2011 Jun.

Article in En | MEDLINE | ID: mdl-21411496

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vasoconstrictor Agents / Vasodilation / Vasopressins / Receptors, Vasopressin / Antidiuretic Agents / Hypotension Limits: Animals / Humans / Male Language: En Journal: J Pharmacol Exp Ther Year: 2011 Document type: Article Affiliation country:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google